Indivior Plans to Relocate Primary Listing to New York, Citing US Market Opportunities

The British pharmaceutical company aims to move its primary listing from the London Stock Exchange to New York, following increased demand for its opioid treatments in the US.

• Indivior, known for its opioid addiction and schizophrenia treatments, intends to shift its primary listing to the US, potentially as early as this summer.
• The move is propelled by the significant US market opportunity for its products, with nearly half of its shares already owned by US investors.
• Shares in Indivior surged by as much as 22% following the announcement, marking the highest increase since late November.
• The relocation is part of a broader trend of companies leaving the London Stock Exchange, raising concerns about London's status as a leading financial hub.
• Indivior's decision comes amid efforts by UK ministers to reform listing regulations to make London a more attractive market for companies.

3 Articles

Evening Standard The Guardian The Telegraph